A patient‐oriented risk–benefit analysis of pathogen‐inactivated blood components: application to apheresis platelets in the United States

S Kleinman, W Reed, A Stassinopoulos - Transfusion, 2013 - Wiley Online Library
We performed a risk–benefit analysis for implementation of pathogen‐inactivated (PI)
apheresis platelets (APs) in the U nited S tates, focusing on the amotosalen/ultraviolet‐A …
被引用次数：61 相关文章

[引用][C] A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States

S KLEINMAN, W REED… - Transfusion …, 2013 - pascal-francis.inist.fr
A patient-oriented risk-benefit analysis of pathogen-inactivated blood components:
application to apheresis platelets in the United States CNRS Inist Pascal-Francis CNRS …

A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States.

S Kleinman, W Reed, A Stassinopoulos - Transfusion, 2013 - search.ebscohost.com
We performed a risk-benefit analysis for implementation of pathogen-inactivated (PI)
apheresis platelets (APs) in the United States, focusing on the amotosalen/ultraviolet-A …

A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States

S Kleinman, W Reed, A Stassinopoulos - Transfusion, 2013 - pubmed.ncbi.nlm.nih.gov
We performed a risk-benefit analysis for implementation of pathogen-inactivated (PI)
apheresis platelets (APs) in the United States, focusing on the amotosalen/ultraviolet-A …

A patient‐oriented risk–benefit analysis of pathogen‐inactivated blood components: application to apheresis platelets in the United States

S Kleinman, W Reed, A Stassinopoulos - Transfusion, 2013 - infona.pl
We performed a risk–benefit analysis for implementation of pathogen‐inactivated (PI)
apheresis platelets (APs) in the U nited S tates, focusing on the amotosalen/ultraviolet‐A …

A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States.

S Kleinman, W Reed, A Stassinopoulos - Transfusion, 2012 - europepmc.org
We performed a risk-benefit analysis for implementation of pathogen-inactivated (PI)
apheresis platelets (APs) in the United States, focusing on the amotosalen/ultraviolet-A …

[引用][C] A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States

S KLEINMAN, W REED, A STASSINOPOULOS - Transfusion, 2013 - Wiley